cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Zymeworks Inc
9 own
14 watching
Current Price
$9.7
$-0.12
(-1.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
598.44M
52-Week High
52-Week High
10.8
52-Week Low
52-Week Low
4.11
Average Volume
Average Volume
0.48M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization598.44M
icon52-Week High10.8
icon52-Week Low4.11
iconAverage Volume0.48M
iconDividend Yield--
iconP/E Ratio--
What does the Zymeworks Inc do?
N/A
Read More
How much money does Zymeworks Inc make?
News & Events about Zymeworks Inc.
Business Wire
14days ago
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks management will participate in...
PR Newswire
20days ago
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating...
Insider Monkey
1month ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2022 Earnings Call Transcript November 9, 2022 Jazz Pharmaceuticals plc beats earnings expectations. Reported EPS is $5.17, expectations were $4.66. Operator: Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call...
GeekWire
1month ago
Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks lead drug candidate, zanidatamab, in the U.S., Europe and Japan. The new cash builds on a $50 million payment earlier this year and comes after Tuesdays release of positive ...
Business Wire
1month ago
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: JP Morgan Healthcare Conference. Zymeworks management will participate in one-on-one meetings...
Frequently Asked Questions
Frequently Asked Questions
What is Zymeworks Inc share price today?
plus_minus_icon
Can Indians buy Zymeworks Inc shares?
plus_minus_icon
How can I buy Zymeworks Inc shares from India?
plus_minus_icon
Can Fractional shares of Zymeworks Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Zymeworks Inc stocks?
plus_minus_icon
What is today’s traded volume of Zymeworks Inc?
plus_minus_icon
What is today’s market capitalisation of Zymeworks Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Zymeworks Inc?
plus_minus_icon
What percentage is Zymeworks Inc down from its 52-Week High?
plus_minus_icon
What percentage is Zymeworks Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.7
$-0.12
(-1.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00